RT Journal Article
SR Electronic
T1 Two-Step Machine Learning to Diagnose and Predict Involvement of Lungs in COVID-19 and Pneumonia using CT Radiomics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.15.22276090
DO 10.1101/2022.06.15.22276090
A1 Khaniabadi, Pegah Moradi
A1 Bouchareb, Yassine
A1 Al-Dhuhli, Humoud
A1 Shiri, Isaac
A1 Al-Kindi, Faiza
A1 Khaniabadi, Bita Moradi
A1 Zaidi, Habib
A1 Rahmim, Arman
YR 2022
UL http://medrxiv.org/content/early/2022/06/16/2022.06.15.22276090.abstract
AB Objective We aimed to develop a two-step machine learning (ML) based model to diagnose and predict involvement of lungs in COVID-19 and non COVID-19 pneumonia patients using CT chest radiomic features.Methods Three hundred CT scans (3-classes: 100 COVID-19, 100 pneumonia, and 100 healthy subjects) were enrolled in this study. Diagnostic task included 3-class classification. For severity prediction, two radiologists scored involvement of lungs in COVID-19 and pneumonia scans based on percentage of involvement in all 5 lobes. Datasets were classified into mild (0-25%), moderate (26-50%), and severe (>50%). Whole lungs were segmented utilizing deep learning-based segmentation method. Altogether, 107 features including shape, first-order histogram, second and high order texture features were extracted. For both tasks, datasets were randomly divided into 90% training sets (70% and 30% for training and validation, respectively) and 10% test sets. Pearson correlation coefficient (PCC≥90%) was performed to exclude highly correlated features. Subsequently, different feature selection algorithms (Correlation attribute evaluation, Information gain attribute, Wrapper Subset selection algorithm, Relief method, and Correlation-based feature selection) were assessed. The most pertinent features were finally selected using voting method based on the evaluation of all algorithms. Several ML-based supervised algorithms were utilized, namely Naïve Bays, Support Vector Machine, Bagging, Random Forest, K-nearest neighbors, Decision Tree and Ensemble Meta voting. The synthetic minority oversampling technique (SMOTE) was used to balance the three classes in training sets. The optimal model was first selected based on precision, recall and area-under-curve (AUC) by randomizing the training/validation sets 20 times, followed by testing using the test set. To ensure the repeatability of the results, the entire process was repeated 50 times.Results Nine pertinent features (2 shape, 1 first-order, and 6 second-order features) were obtained after feature selection for both phases. In diagnostic task, the performance of 3-class classification using Random Forest was 0.909±0.026, 0.907±0.056, 0.902±0.044, 0.939±0.031, and 0.982±0.010 for precision, recall, F1-score, accuracy, and AUC, respectively. The severity prediction task using Random Forest achieved 0.868±0.123 precision, 0.865±0.121 recall, 0.853±0.139 F1-score, 0.934±0.024 accuracy, and 0.969±0.022 AUC.Conclusion The two-phase ML-based model accurately classified COVID-19 and pneumonia patients using CT radiomics, and adequately predicted severity of lungs involvement. This 2-steps model showed great potential in assessing COVID-19 CT images towards improved management of patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Omani Research Council Grant, grant number RC/COVID-MED/RADI/20/01.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SQUH and ROYH medical research ethical committees both approved this retrospective study (MREC#1254-REF. NO. SQU-EC/121/20)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.